Smz1

Phase 3

Smz1 is one of 3 therapeutic programs targeting Neovascular (Wet) Age-Related Macular Degeneration. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Neovascular (wet) Age-Related Macular DegenerationRecruiting

Neovascular (wet) Age-Related Macular DegenerationPhase 3

Recruiting

Competition

Competitive Landscape

3 competitors in Neovascular (wet) Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Smz1

SSANGMYUNG innovation

Phase 3

1 2

4d-150 Ivt

44D Molecular Therapeutics

Preclinical

1 3

Aflibercept IVT

44D Molecular Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Neovascular (wet) Age-Related Macular Degeneration

NCT07695207

Clinical

Trials by Indication[1]

Neovascular (Wet) Age-Related Macular Degeneration1 trial

A 12-month, Randomization, Double-blind, Placebo-controlled, Parallel, Multicenter-Phase 3 Trial to Evaluate the Safety and Efficacy of SMZ1 Tablet in Combination With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy

Recruiting·SSANGMYUNG innovation·Phase 3·NCT07695207·266 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Smz1. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Smz1. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — SANGMYUNG innovation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: SSANGMYUNG innovation

Smz1

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Neovascular (Wet) Age-Related Macular Degeneration1 trial

References

Drug Info

Quick Facts

Related News